<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

The Different Impact of BRCA Mutations on the Survival of Epithelial Ovarian Cancer Patients: A Retrospective Single-Center Experience

descriptionPublicationkeyboard_double_arrow_right Article 01 Jan 2013 English Publisher:S. Karger AGJournal:Oncology, volume 85, pages 122-127 (issn: 0030-2414, eissn: 1423-0232,

Authors: Antonino Ditto; Barbara Grijuela; Francesco Raspagliesi; G. Spatti; Maria Laura Mancini; Federico Cirillo; Domenica Lorusso;

doi: 10.1159/000353786

pmid: 23941904

The Different Impact of BRCA Mutations on the Survival of Epithelial Ovarian Cancer Patients: A Retrospective Single-Center Experience

- Summary
- Subjects
- Related research
  (92)
- Metrics

Abstract

Objectives: The objective of this study was to examine whether the oncologic outcomes of BRCA1-associated and BRCA2-associated ovarian cancers correlate differently. Methods: Genetic data and clinical characteristics were correlated with progression-free survival (PFS) and overall survival (OS). Results: Data from 147 BRCA-mutated patients (119 BRCA1-positive and 28 BRCA2-positive) were analyzed. At a median follow-up of 69 months, the median PFS was 27.2 and 45.46 months for BRCA1 and BRCA2 patients, respectively (p = 0.03). Median OS was 77.23 and 111.47 months for BRCA1 and BRCA2 patients, respectively (p = 0.08). Conclusion:BRCA2 mutations confer PFS and a trend to OS advantage compared with the BRCA1 mutation in BRCA-mutated epithelial ovarian cancer patients.

Related Organizations

Fondazione IRCCS Istituto Nazionale dei Tumori
Italy

Keywords

Adult, BRCA2 Protein, Ovarian Neoplasms, BRCA1 Protein, Kaplan-Meier Estimate, Adenocarcinoma, Carcinoma, Ovarian Epithelial, Middle Aged, Combined Modality Therapy, Disease-Free Survival, Multivariate Analysis, Humans, Female, Neoplasms, Glandular and Epithelial, Aged, Proportional Hazards Models, Retrospective Studies

Filter by relation

All relations

arrow_drop_down

92 Research products, page 1 of 10

New Candidate Predisposition Genes for Hereditary Breast Cancer: SLIT3, CREB3, USP39
2021IsAmongTopNSimilarDocuments
Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma
2020IsAmongTopNSimilarDocuments
Mutant BRCA2
2017IsRelatedTo
Truncated breast and ovarian cancer susceptibility protein 2
2017IsRelatedTo
Truncated breast and ovarian cancer susceptibility protein 2
2017IsRelatedTo
Truncated breast and ovarian cancer susceptibility protein 2
2017IsRelatedTo
Frequency of BRCA1 and BRCA2 Mutations in Individuals with Breast and Ovarian Cancer in a Chinese Hakka Population Using Next-Generation Sequencing
2019IsAmongTopNSimilarDocuments
Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
2020IsAmongTopNSimilarDocuments
Testing for Hereditary Risk of Breast and Ovarian Cancer
2000IsAmongTopNSimilarDocuments
The Molecular Pathology of Hereditary Breast Cancer
2008IsAmongTopNSimilarDocuments

chevron_left
1
2
3
4
5
chevron_right

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	10
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%